Brightgene Bio-Medical Technology Co.,Ltd. (688166) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

688166 Brightgene Bio-Medical Technology Co.,Ltd.

Watchlist

33.12
+0.36+1.10%

Market Closed Dec 4 15:00 CST

13.99BMarket Cap74.43P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Brightgene Bio-Medical Technology Co.,Ltd. (688166.SH): BGM0504 injection indications have obtained ethical approval for Phase III clinical trials.
Ge Longhui December 4th, brightgene bio-medical technology co.,ltd. (688166.SH) announced that its wholly-owned subsidiary Brightgene New Creation Biomedical Technology (Wuxi) Co., Ltd. (referred to as "Brightgene New Creation") independently developed BGM0504 injection for lowering blood glucose indication Phase III clinical research protocol has been approved by the leading hospital Peking University People's Hospital Ethics Review Committee and obtained the "Peking University People's Hospital Ethics Review Committee Ethics Review Letter". BGM0504 injection is the company's independently developed GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) dual receptor stimulation.
Gelonghui FinanceDec 4 03:21 ET
Brightgene bio-medical technology co.,ltd. (688166.SH): Dinoprostone tablets and its active pharmaceutical ingredient, as well as the active pharmaceutical ingredient for levo-dihydroxyphenylserine, have been approved for marketing.
brightgene bio-medical technology co.,ltd. (688166.SH) announced that its wholly-owned subsidiary, brightgene pharmaceutical (suzhou) co., ltd...
Zhitong FinanceDec 3 03:16 ET
Brightgene bio-medical technology co.,ltd. (688166.SH): Subsidiary obtains pharmaceutical registration certificate and approval notice for chemical raw materials listing application.
Brightgene Bio-Medical Technology Co.,Ltd. (688166.SH) announced on December 3 that its wholly-owned subsidiary Brightgene Pharmaceutical (Suzhou) Co., Ltd. has received the "Dienogest Tablets" pharmaceutical registration certificate issued by the National Medical Products Administration, as well as the "Dienogest" and "Succinylcholine Chloride" chemical raw materials for marketing approval notification letter.
Gelonghui FinanceDec 3 03:10 ET
Is BrightGene Bio-Medical Technology (SHSE:688166) A Risky Investment?
Simply Wall StNov 29 19:39 ET
BrightGene Bio-Medical Technology's (SHSE:688166) Earnings Have Declined Over Three Years, Contributing to Shareholders 13% Loss
Simply Wall StNov 8 20:10 ET
Third Quarter Report 2024
SZSIOct 29 12:00 ET · Announcements

Comments

Moomoo AI

Jan 31 19:13

Despite high P/E ratio and slower growth, investors hope for a business turnaround. However, if P/E aligns with recent growth rates, shareholders may face disappointment. Weak earnings and slower market growth suggest share price risk, posing significant risk to shareholders and potential investors.

BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 31% Share Price Plunge Could Signal Some Risk

Moomoo AI

Dec 17, 2023 18:19

With shrinking earnings and below market growth rates, it's hard to justify the high P/E ratio. Absent swift medium-term improvements, shares might drop and with it the P/E ratio. Current soaring prices may be risky, posing potential threats to investors.